文献速递主动脉疾病

高手术风险患者中医师改良内分支腔内修复术的初步结局

Initial Outcomes of Physician-Modified Inner Branched Endovascular Repair in High-Surgical-Risk Patients.
PubMed 文献 · J Endovasc Ther · 2023-04-27

这项回顾性单中心研究纳入10例高手术风险患者(6例男性;中位年龄83.0岁),采用医师改良内分支腔内修复术(PMiBEVAR)治疗肾旁动脉瘤、胸腹主动脉瘤和主动脉弓动脉瘤。按患者计算的技术成功率为90.0%(9/10),按血管计算为93.3%(14/15),临床成功率为90%(9/10),院内死亡2例且与动脉瘤无关。作者认为PMiBEVAR对复杂动脉瘤可行,但长期耐久性尚未确定,需进一步大规模长期研究。

要点

  • PMiBEVAR用于高手术风险患者的肾旁、胸腹和弓部动脉瘤,按患者技术成功率90.0%(9/10)。
  • 按血管技术成功率为93.3%(14/15),临床成功率为90%(9/10)。
  • 院内死亡2例与动脉瘤无关,随访超过6个月时4例瘤囊缩小、1例稳定。

核心结论

  • PMiBEVAR是治疗高手术风险患者复杂动脉瘤的可行方法,可能从改善解剖适应性、无时间延迟和许多国家可实施性方面补充现有技术,但长期耐久性尚未确定,需进一步大规模长期研究。

研究设计与样本

  • 回顾性单中心研究,纳入10例(6例男性;中位年龄83.0岁)接受PMiBEVAR治疗的患者,均为因严重合并症(美国麻醉医师协会体能状态评分≥3或急诊修复)而处于高手术风险者。

主要发现

  • 3例肾旁动脉瘤、4例胸腹主动脉瘤和3例主动脉弓动脉瘤,通过内分支重建12条肾-肠系膜动脉和3条左锁骨下动脉。
  • 按患者技术成功率为90.0%(9/10),按血管技术成功率为93.3%(14/15),临床成功率为90%(9/10)。
  • 院内死亡2例,与动脉瘤无关;截瘫和胆固醇栓塞分别发生于2例患者;3例患者术后机械通气延长3天。
  • 随访超过6个月后,4例患者瘤囊缩小,1例患者动脉瘤大小稳定,无患者需要干预。

临床怎么用

  • 作者认为PMiBEVAR是治疗高手术风险患者复杂动脉瘤的可行方法,可能从改善解剖适应性(相比现货器械)、无时间延迟(相比定制器械)和许多国家可实施性方面补充现有技术。
  • 作者指出手术时间因病例差异很大,提示存在学习曲线,并需要技术创新以实现更一致的手术。

局限性

  • 长期耐久性尚未确定。
  • 需进一步大规模长期研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To report the initial outcomes of physician-modified inner branched endovascular repair (PMiBEVAR) for pararenal aneurysms (PRAs), thoracoabdominal aortic aneurysms (TAAAs), and aortic arch aneurysms in high-surgical-risk patients. MATERIALS AND METHODS: A total of 10 patients (6 men; median age, 83.0 years) treated using PMiBEVAR were enrolled in this retrospective, single-center study. All patients were at high surgical risk because of severe comorbidities (American Society of Anesthesiologists physical status score≥3 or emergency repair). End points were defined as technical success per patient and per vessel (successful deployment), clinical success (no endoleaks postoperatively), in-hospital death, and major adverse events. RESULTS: There were 3 PRAs, 4 TAAAs, and 3 aortic arch aneurysms with 12 renal-mesenteric arteries and 3 left subclavian arteries incorporated by inner branches. The technical success rate was 90.0% (9/10) per patient and 93.3% (14/15) per vessel. The clinical success rate was 90% (9/10). There were 2 in-hospital deaths, unrelated to aneurysms. Paraplegia and shower emboli occurred separately in 2 patients. Three patients experienced prolonged ventilation for 3 days after surgery. Aneurysm sac shrinkage occurred in 4 patients, and aneurysm size stabilized in 1 patient during follow-up, more than 6 months later. None of the patients required intervention. CONCLUSION: PMiBEVAR is a feasible approach for treating complex aneurysms in high-surgical-risk patients. This technology may complement the existing technology in terms of improved anatomical adaptability, no time delay and practicability in many countries. However, long-term durability remains undetermined. Further large-scale and long-term studies are needed. CLINICAL IMPACT: This is the first clinical study to investigate outcomes of physician-modified inner branched endovascular repair (PMiBEVAR). PMiBEVAR for treating pararenal aneurysm, thoracoabdominal aortic aneurysm, or aortic arch aneurysm is a feasible procedure. This technology is likely to complement existing technology in terms of improved anatomical adaptability (compared to off-the-shelf devices), no time delay (compared to custom-made devices), and the potential to be performed in many countries. On the other hand, surgery time varied greatly depending on the case, suggesting a learning curve and the need for technological innovation to perform more consistent surgeries.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Shibata T, Iba Y, Nakajima T, et al. Initial Outcomes of Physician-Modified Inner Branched Endovascular Repair in High-Surgical-Risk Patients. J Endovasc Ther. 2023. PMID: 37102596. doi:10.1177/15266028231169183

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。